Personalized activity index a new safety monitoring tool for multiple sclerosis clinical trials

摘要

BackgroundAn abnormal increase of contrast-enhancing lesion (CEL) counts on frequent MRIs is interpreted as a signal of potential worsening in multiple sclerosis (MS) clinical trials. We demonstrate the utility of the MR personalized activity index (MR-pax) to identify such increases.